*Prices reflect U.S. average retail price

Glipizide is an oral rapid- and short-acting anti-diabetic medication from the sulfonylurea class. It is classified as a second-generation sulfonylurea, which means that it undergoes enterohepatic circulation. Second-generation sulfonylureas are both more potent and have shorter half-lives than the first-generation sulfonylureas. Originally available in 1984, it is marketed by Pfizer under the brand name Glucotrol in the USA, where Pfizer sells Glucotrol in doses of 5 and 10 milligrams and Glucotrol XL (an extended release form of glipizide) in doses of 2.5, 5, and 10 milligrams... Wikipedia

Manufacturer's Website: Not Available                                                                                                                   Average retail cost: $225/month

Glipizide is an oral rapid- and short-acting anti-diabetic medication from the sulfonylurea class. It is classified as a second-generation sulfonylurea, which means that it undergoes enterohepatic circulation. Second-generation sulfonylureas are both more potent and have shorter half-lives than the first-generation sulfonylureas. Originally available in 1984, it is marketed by Pfizer under the brand name Glucotrol in the USA, where Pfizer sells Glucotrol in doses of 5 and 10 milligrams and Glucotrol XL (an extended release form of glipizide) in doses of 2.5, 5, and 10 milligrams... Wikipedia

Manufacturer's Website: Not Available                                                                                                           Average retail cost: $323/month

Glibenclamide, also known as glyburide, is an antidiabetic drug in a class of medications known as sulfonylureas, closely related to sulfonamide antibiotics. It was developed in 1966 in a cooperative study between Boehringer Mannheim (now part of Roche) and Hoechst (now part of Sanofi-Aventis)... Wikipedia

Manufacturer's Website: Not Available                                                                                                                                  Average retail cost: $343/month

Glimepiride (original trade name Amaryl) is an orally available medium-to-long-acting sulfonylurea antidiabetic drug. It is sometimes classified as either the first third-generation sulfonylurea, or as second-generation... Wikipedia

Manufacturer's Website: Not Available                                                                                                                   Average retail cost: $982/month

The trade form of this drug is no longer available as it has been discontinued by the manufacturer.

The trade form of this drug is no longer available as it has been discontinued by the manufacturer.

The trade form of this drug is no longer available as it has been discontinued by the manufacturer.

The trade form of this drug is no longer available as it has been discontinued by the manufacturer.